cemiplimab + REGN7075
Phase 2Small molecule
cemiplimab + REGN7075 is one of 35 small molecule programs targeting Colorectal Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Eylea
RegeneronPreclinical
PORTRAZZA
Eli LillyPreclinical
Emend IV
Merck & Co.Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Gas-X
PPortuguese Oncology Institute, Coimbra
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Ketalar
AAultman Health Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for cemiplimab + REGN7075. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNSABP Foundation Inc